SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Emcure Pharmaceuticals jumps on getting nod for acquiring 20.42% stake of Zuventus Healthcare

23 Jun 2025 Evaluate

Emcure Pharmaceuticals is currently trading at Rs. 1337.45, up by 25.10 points or 1.91% from its previous closing of Rs. 1312.35 on the BSE.

The scrip opened at Rs. 1314.95 and has touched a high and low of Rs. 1348.00 and Rs. 1304.65 respectively. So far 1739 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1577.50 on 18-Sep-2024 and a 52 week low of Rs. 890.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1377.35 and Rs. 1291.35 respectively. The current market cap of the company is Rs. 25375.17 crore.

The promoters holding in the company stood at 77.92%, while Institutions and Non-Institutions held 6.51% and 15.57% respectively.

Emcure Pharmaceuticals has received approval for the acquisition of 4,095,180 equity shares, constituting 20.42% of the total issued and paid-up capital of Zuventus Healthcare (Zuventus), a subsidiary of the company, from all its individual shareholders, thereby making Zuventus a wholly-owned subsidiary of the company.

The Board of Directors of the company at its meeting held on June 21, 2025, has approved the same.

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Emcure Pharma Share Price

1678.50 36.90 (2.25%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×